A Strategic Approach to Addressing Aggressive Vertebral Hemangiomas With Hypofractionated Stereotactic Body Radiotherapy
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
This case report describes the treatment of a recurrent T2 vertebral hemangioma in a 46-year-old man who had prior decompression and fusion surgery. Despite initial stability, the patient developed worsening symptoms, leading to a comprehensive approach involving embolization, microscopic excision, and posterior fixation. Recurrence prompted the choice of Stereotactic Body Radiotherapy (SBRT) over redo surgery. Administered with 30 Gy in five fractions, SBRT significantly reduced hemangioma size and resolved neurological symptoms. The case highlights the effectiveness of hypofractionated SBRT as a promising intervention for aggressive vertebral hemangiomas.
References
1.
Conti A, Starnoni D, Barges-Coll J, Papadimitriou K, Levivier M, Tuleasca C
. Radiosurgery for Benign Vertebral Body Hemangiomas of the Spine: A Systematic Review and Meta-Analysis. World Neurosurg. 2022; 164:97-105.
DOI: 10.1016/j.wneu.2022.03.120.
View
2.
Kalash R, Glaser S, Flickinger J, Burton S, Heron D, Gerszten P
. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?. J Neurosurg Spine. 2018; 29(2):220-225.
PMC: 7425586.
DOI: 10.3171/2017.12.SPINE17920.
View
3.
Rades D, Bajrovic A, Alberti W, Rudat V
. Is there a dose-effect relationship for the treatment of symptomatic vertebral hemangioma?. Int J Radiat Oncol Biol Phys. 2002; 55(1):178-81.
DOI: 10.1016/s0360-3016(02)03734-3.
View
4.
Goldstein C, Varga P, Ziya L Gokaslan , Boriani S, Luzzati A, Rhines L
. Spinal hemangiomas: results of surgical management for local recurrence and mortality in a multicenter study. Spine (Phila Pa 1976). 2015; 40(9):656-64.
DOI: 10.1097/BRS.0000000000000840.
View
5.
Zeng K, Tseng C, Soliman H, Weiss Y, Sahgal A, Myrehaug S
. Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview. Front Oncol. 2019; 9:337.
PMC: 6504814.
DOI: 10.3389/fonc.2019.00337.
View